ITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" Therapies

ITSC​​ 治疗白血病：NCTN“个体化”治疗的新型分子策略

• 批准号: 10372019
• 负责人: JOHN C. BYRD
• 金额: $ 66.33万
• 依托单位: UNIVERSITY OF CINCINNATI
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-03 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10372019
• 关键词: Achievement; Adult; Area; Atmosphere; Center for Translational Science Activities; Clinical; Clinical Trials; Collaborations; Creativeness; Data; Development; Disease; Fostering; Funding; Genetic; Genetic Markers; Genomics; Goals; Individual; Infrastructure; International; Malignant Neoplasms; Molecular; Molecular Abnormality; Molecular Profiling; National Cancer Institute; National Clinical Trials Network; Oncology; Outcome; Patient-Focused Outcomes; Patients; Pharmacologic Substance; Phase; Pilot Projects; Protocols documentation; Research; Research Personnel; Sampling; Science; Southwest Oncology Group; System; Technology; Testing; Therapeutic; Therapeutic Trials; Tissues; Translating; United States; Work; adult leukemia; cancer type; clinical translation; clinically relevant; community involvement; curative treatments; design; epigenetic marker; epigenomics; experience; genetic predictors; improved; individualized medicine; innovation; leukemia; leukemic transformation; leukemogenesis; neoplastic; next generation; novel; participant enrollment; prognostic; programs; rational design; targeted treatment; therapeutic target; therapy resistant; translational medicine; treatment response; treatment strategy; tumor

PROJECT SUMMARY Advances in understanding the molecular basis of leukemia, together with the wealth of emerging innovative pharmaceutical compounds, have brought great opportunities to improve the clinical outcome of patients. To maximize the value of these discoveries, it is imperative to demonstrate our ability to molecularly characterize individual tumors and apply this information to enroll patients onto therapeutic protocols that match distinct molecular profiles to specific targeting treatments—all within the context of an effective cancer therapeutic trials' system. To create an atmosphere for both research creativity and rapid clinical translation of novel discoveries into treatment approaches of adult leukemia patients, the Alliance for Clinical Trials in Oncology (hereafter called Alliance) Leukemia Correlative Science Committee (A-LCSC), and the SWOG Leukemia Translational Medicine Subcommittee (S-LTMS) and the Broad Institute have elected to joined forces in 2014 and created an Integrated Translational Science Center for Leukemia (ITSC-L). The overall goal of the ITSC-L is to identify the genetic and molecular aberrations that characterize leukemic transformation, understand their contribution to therapeutic response or resistance, and utilize this information for the design of rational therapeutic trials that match specific molecular aberrations to emerging targeted therapies. These goals will be achieved through the carefully selection of Pilot Studies that involve outstanding investigators working within Alliance and SWOG and those working outside the groups. Ultimately, these efforts should not only result in a significant improvement in the clinical outcome for leukemia patients, but are expected to generate cutting-edge findings applicable to other types of cancer. The Specific Aims of this Program are the following: Specific Aim 1. To maintain an Integrated Translational Science Center for Leukemia (ITSC-L) that will promote research among investigators working within the NCI National Clinical Trials Network (NCTN) system and outside the system by providing and coordinating funding, expertise, technology, tissue and data for innovative studies with clinical relevance; Specific Aim 2. To identify novel prognostic and predictive genetic and epigenetic markers and therapeutic targets for the development of innovative therapeutic paradigms that transform the current approach to leukemia patients and improve their cure rate; Specific Aim 3. To rapidly integrate high impact correlative science into early and late phase therapeutic trials of leukemia supported by the NCTN.

项目摘要 了解白血病的分子基础的进步以及新兴创新的丰富 药物化合物为改善患者的临床结果带来了巨大的机会 最大化发现的价值，必须证明我们的能力可以宽容地表征 单个肿瘤并应用Inforll患者on thrion 特定靶向治疗治疗的分子特征 - 在有效的癌症治疗试验的背景下 系统。 进入成人白血病患者的治疗方法，肿瘤学临床联盟（以下称为 联盟）白血病相关科学委员会（A-LCSC）和SWOG白血病转化医学 小组委员会（S-LTMS）和Broad Institute已于2014年发行了联合，并创建了一个综合的 白血病转化科学中心（ITSC-L）。 和分子畸变，使白血病转化，了解它们对治疗的贡献 呼吸或抵抗，并利用此信息来设计理性的曲式试验 针对有针对性的疗法的分子畸变将仔细地疼痛 选择试点研究，涉及在联盟中工作的杰出研究人员 在群体之外工作。 白血病患者的临床结果，但有望产生适用于其他的最先进发现 癌症的类型。 特定目的1。要维护一个综合的白血病科学中心（ITSC-L），它将 促进研究人员之间的研究工作，在工作工作工作的工作工作工作，纳森国家临床网络（NCTN） 通过提供和协调资金，专业知识，技术，组织和系统的系统和外部系统 具有临床相关性的创新研究数据； 遗传和表观遗传标记以及用于发展创新治疗范例的治疗靶标 转化当前的白血病患者的方法，并提高其特定目的。 将高影响力相关科学纳入早期蚂蚁晚期治疗试验的白血病治疗试验 NCTN。